Filing scope and business context
Important identity caveat: Although the request identifies Korro Bio, this is Frequency Therapeutics, Inc.’s Form 10-Q for the quarter ended September 30, 2023, filed November 2, 2023. It reports Frequency’s pre-merger results, not standalone Korro Bio results or the combined company’s financials.
Frequency was a preclinical-stage biotechnology company with no product-sales revenue. After its FX-322 Phase 2b study failed its primary endpoint, it discontinued its hearing programs and reduced headcount. On July 14, 2023, Frequency and Korro Bio entered into a merger agreement; the filing says the combined company’s business would be Korro Bio’s. The filing does not establish that the merger had closed by September 30.
Financial results and liquidity
Amounts below are in millions of dollars unless noted. The company reported no product-sales revenue; gross margin is therefore not applicable.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Research and development expense | $2.6 | $11.7 | $18.5 | $38.8 |
| General and administrative expense | $10.1 | $8.6 | $26.5 | $26.0 |
| Total operating expenses | $12.7 | $20.3 | $45.0 | $64.8 |
| Net loss | $11.6 | $19.5 | $42.0 | $64.2 |
| Basic and diluted loss per share | $0.31 | $0.55 | $1.17 | $1.83 |
| Cash used in operating activities | Not provided for quarter | Not provided for quarter | $27.4 | $42.6 |
At September 30, cash and cash equivalents were $41.7 million; restricted cash was $2.0 million, making cash, cash equivalents and restricted cash $43.7 million. There were no marketable securities. Total assets were $46.3 million, total liabilities $9.6 million, and stockholders’ equity $36.7 million. The company had repaid its term loan in April 2023 and reported no debt outstanding at quarter-end. Current assets of $42.5 million compared with current liabilities of $9.6 million.
Changes, outlook, and notable items
- Q3 operating expenses fell 38% year over year, mainly as discontinued hearing programs and workforce reductions lowered R&D spending. G&A rose 18%, primarily from higher professional and legal fees. Q3 net loss narrowed by $7.9 million.
- Nine-month operating cash use declined to $27.4 million from $42.6 million. Investing activities provided $31.5 million, mainly from marketable-security redemptions; financing activities used $14.1 million, primarily for term-loan repayment.
- Management said available resources and restructuring savings were expected to fund planned operations for at least 12 months from when the financial statements were available to be issued. The filing provides no standalone Korro or combined-company financial forecast. Frequency said it did not expect to continue developing its own programs following the merger.
- Frequency recorded $4.3 million of restructuring-related expenses in the first nine months, including severance, accelerated depreciation, and hearing-program costs. It accrued a $1.675 million legal settlement at September 30; the parties agreed to resolve the matter on October 31. A separate securities class action dismissal was under appeal, and the company said it could not estimate a possible loss.
- The Lexington office lease and sublease were set to terminate January 31, 2024. The ATM equity program was terminated September 26, 2023. The Astellas collaboration and several technology licenses had also been terminated.
- Management reported disclosure controls were effective at the reasonable-assurance level and no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Confirm the requested issuer and reporting scope: this is Frequency Therapeutics’ filing, not a Korro Bio 10-Q.
- Check the merger’s closing status, terms, share conversion and any contingent value rights in the merger documents and subsequent filings.
- Assess the combined company’s cash runway and planned spending; the runway statement here applies to Frequency’s planned operations and is not a Korro-specific forecast.
- Review the $1.675 million settlement payment and the status and potential exposure of the appealed securities litigation.
- Reconcile liquidity figures carefully: $41.7 million is cash and cash equivalents; $43.7 million includes restricted cash.